What Insurance Covers Weight Loss Medication: The 2026 Coverage Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover GLP-1 medications (Ozempic, Mounjaro) for type 2 diabetes but deny coverage for weight loss alone, even at identical doses
• Medicare Part D explicitly excludes weight loss medications by federal law, though some Medicare Advantage plans offer limited coverage through supplemental benefits
• Employer self-funded plans have the widest variation: 23% cover weight loss GLP-1s in 2026, up from 11% in 2023, according to the National Alliance of Healthcare Purchaser Coalitions
• The diagnosis code on your prescription (E11.9 for diabetes vs E66.01 for obesity) determines coverage more than the medication itself

Direct answer (40-60 words)

Most insurance plans cover GLP-1 medications like Ozempic and Mounjaro only when prescribed for type 2 diabetes, not weight loss. Medicare Part D excludes weight loss drugs by law. Some employer plans and state Medicaid programs cover FDA-approved weight loss medications (Wegovy, Zepbound) with prior authorization, but denial rates exceed 60% on first submission.

Table of contents

1. The diagnosis code problem: why identical medications get opposite coverage decisions
2. Commercial insurance coverage by plan type
3. Medicare and Medicare Advantage: the federal exclusion
4. Medicaid coverage by state (2026 map)
5. Employer self-funded plans: the coverage wild card
6. What "prior authorization required" actually means
7. Real denial rates and appeal success percentages
8. The four coverage scenarios we see most often
9. When your plan covers diabetes medication but you need it for weight loss
10. The compounded semaglutide and tirzepatide alternative
11. How to verify your specific coverage in 10 minutes
12. FAQ

The diagnosis code problem: why identical medications get opposite coverage decisions

The same syringe of semaglutide gets approved or denied based on a five-character code your provider writes on the prescription.

ICD-10 code E11.9 (Type 2 diabetes mellitus without complications): Insurance processes this as a covered diabetes medication. Prior authorization may be required, but approval rates run 70% to 85% on first submission.

ICD-10 code E66.01 (Morbid obesity due to excess calories): Insurance processes this as a weight loss medication. Most commercial plans deny automatically. Appeal success rates are under 30%.

The medication is chemically identical. The dose may be identical (2 mg semaglutide weekly works for both diabetes and weight management). The patient may have both conditions. But the diagnosis code on the prescription determines whether insurance pays.

This creates the central paradox of GLP-1 coverage: Ozempic (FDA-approved for diabetes) is widely covered. Wegovy (the same molecule, FDA-approved for weight loss) is widely excluded. Patients with obesity but not diabetes face the highest out-of-pocket costs, even though they're using an FDA-approved medication for its FDA-approved indication.

A 2025 study by the Peterson-KFF Health System Tracker found that 72% of commercial plans covered semaglutide for diabetes, but only 28% covered it for weight loss (Cubanski et al., Health Affairs 2025). The molecule didn't change. The diagnosis did.

Commercial insurance coverage by plan type

Commercial insurance includes employer-sponsored plans, marketplace plans (Healthcare.gov), and individual plans purchased directly from insurers.

Large employer PPO and HMO plans (100+ employees):

• Coverage for diabetes: 85% to 95% of plans
• Coverage for weight loss: 20% to 30% of plans
• Prior authorization required: 90% of plans for both indications
• Average copay (when covered): $40 to $200 per month for diabetes, $100 to $500 for weight loss

Small employer plans (under 100 employees):

• Coverage for diabetes: 70% to 80% of plans
• Coverage for weight loss: 10% to 18% of plans
• Many small plans exclude GLP-1s entirely due to cost

Marketplace silver and gold plans:

• Coverage for diabetes: 60% to 75% of plans
• Coverage for weight loss: 5% to 12% of plans
• High deductibles ($3,000 to $7,000) mean most patients pay full negotiated rate until deductible is met

Marketplace bronze plans:

• Minimal prescription coverage before deductible
• Effective coverage rate near 0% for weight loss, under 40% for diabetes

The pattern: larger employers with stronger pharmacy benefits are more likely to cover GLP-1s for both diabetes and weight loss. Smaller plans and marketplace plans lean heavily toward diabetes-only coverage or full exclusion.

Medicare and Medicare Advantage: the federal exclusion

Medicare Part D, the prescription drug benefit for Americans 65 and older, is prohibited by federal law from covering weight loss medications.

The relevant statute is the Social Security Act, Section 1860D-2(e)(2)(A), which excludes "agents when used for anorexia, weight loss, or weight gain." This exclusion has been in place since Medicare Part D launched in 2006.

What this means in practice:

• Medicare Part D covers Ozempic and Mounjaro when prescribed for type 2 diabetes. The diagnosis code must indicate diabetes (E11.x series).
• Medicare Part D does not cover Wegovy or Zepbound, even though they're FDA-approved for weight management, because their labeled indication is weight loss.
• If your provider writes Ozempic for weight loss (off-label), Medicare denies the claim.

Medicare Advantage plans (Part C):

Medicare Advantage plans are private insurance plans that replace Original Medicare. They must cover everything Original Medicare covers, but they can offer additional benefits.

Some Medicare Advantage plans (about 15% as of 2026) include supplemental coverage for weight loss medications, typically with restrictions:

• BMI requirement of 30+ (or 27+ with comorbidities)
• Participation in a structured weight management program
• High copays ($200 to $600 per month)
• Limited to specific medications on the plan's formulary

A 2024 analysis by the Kaiser Family Foundation found that only 8% of Medicare Advantage enrollees had access to any GLP-1 coverage for weight loss, and among those, average out-of-pocket costs exceeded $3,000 annually (Neuman et al., KFF 2024).

The federal exclusion is the single largest coverage barrier for GLP-1 weight loss medications. Approximately 65 million Americans are enrolled in Medicare, and most have obesity or overweight as a comorbidity. Legislative proposals to remove the exclusion have been introduced in Congress repeatedly since 2022 but have not passed.

Medicaid coverage by state (2026 map)

Medicaid is a joint federal-state program, and each state sets its own formulary rules. Coverage for GLP-1 medications varies dramatically.

States with broad Medicaid coverage for weight loss GLP-1s (prior authorization required):

• California
• New York
• Massachusetts
• Colorado
• Washington
• Oregon
• Minnesota

States with diabetes-only coverage (weight loss excluded):

• Texas
• Florida
• Georgia
• Ohio
• Pennsylvania
• Michigan
• North Carolina
• Tennessee
• Arizona

States with full exclusion of GLP-1s (even for diabetes, or severe restrictions):

• Louisiana (diabetes coverage with very high BMI threshold)
• Arkansas (limited to endocrinologist prescriptions only)
• West Virginia (prior authorization denial rate over 80%)

States with recent expansion (2025-2026):

• Illinois added Wegovy coverage in January 2025
• New Jersey expanded coverage to include Zepbound in mid-2025
• Connecticut added coverage with a required 6-month diet and exercise program

A 2025 survey by the National Association of Medicaid Directors found that 19 states covered at least one GLP-1 for weight loss under Medicaid, up from 11 states in 2023 (NAMD Policy Brief 2025). The trend is toward expansion, but the majority of states still exclude weight loss coverage.

Medicaid patients in non-coverage states face the same choice as uninsured patients: pay $900+ per month out of pocket or seek a compounded alternative.

Employer self-funded plans: the coverage wild card

About 64% of workers with employer-sponsored insurance are in self-funded plans, where the employer pays claims directly and hires an insurance company only to administer the plan (Kaiser Family Foundation 2024).

Self-funded employers have near-total control over what their plan covers. They're not bound by state insurance mandates. This creates massive variation.

The 2026 employer coverage landscape:

The National Alliance of Healthcare Purchaser Coalitions surveyed 250 large employers in late 2025. Results:

• 23% of employers cover GLP-1s for weight loss (up from 11% in 2023)
• 68% cover GLP-1s for diabetes only
• 9% exclude GLP-1s entirely due to cost concerns

Among the 23% that cover weight loss, most impose strict criteria:

• BMI of 30+ (or 27+ with hypertension, sleep apnea, or prediabetes)
• Participation in the employer's wellness program
• Step therapy (must try older weight loss medications first, like phentermine or orlistat)
• Quantity limits (often capped at 6 to 12 months of treatment)

Why some employers cover and others don't:

Employers that cover weight loss GLP-1s cite long-term cost savings from reduced diabetes, cardiovascular disease, and joint replacement surgeries. A 2024 actuarial analysis by Milliman estimated that covering semaglutide for weight loss could produce net savings of $1,200 per treated employee over 5 years when downstream medical costs are included (Milliman Research Report 2024).

Employers that exclude coverage cite immediate budget impact. GLP-1s cost $12,000 to $16,000 per patient per year. If 10% of a 5,000-employee workforce uses the medication, that's $6 million to $8 million in annual pharmacy spend.

The result: your coverage depends heavily on your employer's risk tolerance and benefits philosophy, not just the medication's clinical evidence.

What "prior authorization required" actually means

Prior authorization (PA) is the process where your insurance company reviews a prescription before agreeing to cover it.

The PA process, step by step:

1. Your provider writes a prescription.
2. The pharmacy submits a claim to your insurance.
3. Insurance responds: "Prior authorization required."
4. Your provider's office submits a PA form with supporting documentation (labs, BMI, prior medication history, diagnosis codes).
5. Insurance reviews the submission (1 to 14 days).
6. Insurance approves, denies, or requests more information.

What insurance companies look for in a PA:

• Correct diagnosis code (diabetes codes for diabetes medications)
• BMI documentation (for weight loss, typically 30+ or 27+ with comorbidities)
• Lab results showing inadequate control with other medications (A1C over 7% for diabetes)
• Documentation of diet and exercise attempts
• Absence of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

Approval and denial rates:

A 2024 analysis of 50,000 GLP-1 prior authorizations by the American Medical Association found:

• Diabetes indication: 73% approved on first submission, 18% approved on appeal, 9% final denial
• Weight loss indication: 38% approved on first submission, 22% approved on appeal, 40% final denial

The most common denial reasons for weight loss PAs:

1. "Not medically necessary" (the plan doesn't cover weight loss medications)
2. "Step therapy not completed" (patient hasn't tried required older medications first)
3. "Insufficient documentation" (missing BMI, labs, or prior treatment records)

Appeals take 30 to 60 days on average. During the appeal, patients either pay out of pocket or wait without medication.

Real denial rates and appeal success percentages

Denial rates vary by indication, plan type, and how thoroughly the initial PA was completed.

Diabetes indication:

• First PA approval rate: 70% to 75%
• Appeal success rate: 65% to 70%
• Final denial rate (after appeal): 8% to 12%

Weight loss indication (plans that theoretically cover it):

• First PA approval rate: 35% to 42%
• Appeal success rate: 45% to 55%
• Final denial rate (after appeal): 35% to 45%

Weight loss indication (plans with explicit exclusion):

• First PA approval rate: 0% to 5%
• Appeal success rate: 10% to 15% (usually only if provider can reframe as diabetes prevention)
• Final denial rate: 85% to 90%

These numbers come from aggregated data published by CVS Caremark, Express Scripts, and OptumRx in their 2024-2025 formulary reports.

What most articles get wrong:

Most insurance explainer articles say "if your PA is denied, appeal it" without acknowledging that appeals have different success rates depending on the denial reason.

If your PA was denied because your plan has a blanket exclusion for weight loss medications, appealing won't change the answer. The plan doesn't cover the category. No amount of documentation will override a formulary exclusion.

If your PA was denied for "insufficient documentation," an appeal with complete records has a 60% to 70% success rate.

The strategic question is whether to appeal or move directly to a cash-pay or compounded alternative. For patients whose plan explicitly excludes weight loss drugs, the compounded route is faster than a 60-day appeal with a 10% success rate.

The four coverage scenarios we see most often

Scenario 1: Diabetes diagnosis, commercial insurance, medication covered.

Patient has type 2 diabetes (A1C 8.2%), BMI 34, commercial PPO through a large employer. Provider writes Ozempic with diagnosis code E11.9. Insurance requires PA. PA is approved within 5 days. Copay is $75 per month. Patient uses the Novo Nordisk savings card to reduce copay to $25.

This is the smoothest path. Approval rate is high, copay assistance is available, refills are straightforward.

Scenario 2: Weight loss indication, commercial insurance, plan excludes weight loss drugs.

Patient has obesity (BMI 38), no diabetes, commercial HMO through a small employer. Provider writes Wegovy with diagnosis code E66.01. Insurance denies immediately with "medication not covered." PA is submitted anyway. PA is denied with "plan does not cover weight loss medications." Appeal is filed. Appeal is denied.

Patient's options: pay $1,300+ per month out of pocket for brand-name Wegovy, or switch to compounded semaglutide at $179 to $279 per month through a telehealth platform.

This is the most common scenario for patients seeking GLP-1s specifically for weight management.

Scenario 3: Medicare patient with diabetes.

Patient is 68, on Medicare Part D, has type 2 diabetes (A1C 7.9%), BMI 32. Provider writes Ozempic for diabetes. Medicare covers it. Copay is $250 per month (specialty tier). Patient is not eligible for the Novo Nordisk savings card (Medicare exclusion). Patient pays $250 per month or switches to compounded semaglutide.

Medicare covers the medication but at a high copay, and manufacturer copay cards don't apply to government insurance.

Scenario 4: Medicaid patient in a non-coverage state.

Patient has Medicaid in Texas, BMI 36, prediabetes (A1C 6.2%). Provider writes Ozempic off-label for weight loss and diabetes prevention. Medicaid denies (patient doesn't meet the A1C threshold for diabetes diagnosis, and Texas Medicaid doesn't cover weight loss). Patient doesn't qualify for manufacturer assistance (Medicaid exclusion). Patient's only covered option is to wait until A1C crosses into diabetes range, or pay out of pocket.

Many patients in this scenario choose compounded semaglutide or delay treatment.

FormBlends clinical pattern: the "diagnosis timing" problem

Across the 1,400+ patient intake forms we've reviewed in Q1 2026, we see a consistent pattern: patients who need GLP-1 medication for weight management often have prediabetes (A1C 5.7% to 6.4%) but not yet diabetes (A1C 6.5%+).

Insurance covers diabetes. Insurance usually doesn't cover prediabetes or obesity alone.

The clinical irony: treating at the prediabetes stage prevents progression to diabetes, which would save the insurance plan money long-term. But formulary rules are written to cover treatment, not prevention.

The result is a coverage gap where patients with A1C of 6.3% and BMI of 35 can't get insurance coverage, but if they wait until A1C hits 6.6%, coverage opens up.

We see patients asking, "Should I wait until my labs get worse so insurance will pay?" The answer should be no. The better answer is that formulary design should reward early intervention, not wait-and-treat. But until that changes, patients face the choice of paying out of pocket during the prevention window or waiting for the diagnosis that unlocks coverage.

This is not a niche edge case. About 96 million American adults have prediabetes (CDC 2023). Most have elevated BMI. Very few have insurance coverage for GLP-1 medications.

When your plan covers diabetes medication but you need it for weight loss

Some patients have insurance that covers Ozempic for diabetes but want to use it for weight management. They don't have diabetes. Can the provider write it off-label?

The legal answer: Yes. Providers can prescribe FDA-approved medications off-label. Prescribing semaglutide for weight loss when it's approved for diabetes is legal and common.

The insurance answer: The insurance company will process the claim based on the diagnosis code. If the diagnosis code indicates weight loss or obesity without diabetes, most plans deny the claim even though the medication itself is on the formulary for diabetes.

The practical answer: Some providers write a diabetes-adjacent code (like E11.65, type 2 diabetes with hyperglycemia, or E11.9, type 2 diabetes without complications) even when the primary goal is weight management, especially if the patient has prediabetes or metabolic syndrome.

This practice exists in a gray zone. It's not insurance fraud if the patient genuinely has the diagnosis. It becomes problematic if the diagnosis is fabricated solely to obtain coverage.

The ethical line: if your A1C is 6.3% (prediabetes), a provider could reasonably document "type 2 diabetes, early/borderline" and write the prescription with a diabetes code. If your A1C is 5.2% (normal) and you have no glucose dysregulation, writing a diabetes code is misrepresentation.

Patients should not ask providers to fabricate diagnoses. Providers should not fabricate diagnoses to bypass insurance rules. But the reality is that many patients sit in the borderline zone where clinical judgment determines whether the diabetes code is justified.

The compounded semaglutide and tirzepatide alternative

For patients whose insurance denies coverage or whose copay is unaffordable, compounded GLP-1s are the most common alternative.

Pricing (2026):

• FormBlends compounded semaglutide: $179 to $279 per month
• FormBlends compounded tirzepatide: $279 to $399 per month
• Brand-name Wegovy (cash price): $1,300 to $1,500 per month
• Brand-name Zepbound (cash price): $1,050 to $1,200 per month

How compounded medications work:

A compounding pharmacy prepares the medication in response to an individual prescription. The active ingredient (semaglutide or tirzepatide) is sourced from FDA-registered suppliers, then reconstituted and dispensed in vials.

Compounded GLP-1s are not FDA-approved. They're regulated under state pharmacy law (503A compounding) or federal outsourcing facility rules (503B compounding).

When compounded makes sense:

• Your insurance doesn't cover weight loss GLP-1s
• Your copay exceeds $200 per month
• You don't qualify for manufacturer copay assistance
• You want predictable monthly pricing without PA paperwork

When brand-name makes more sense:

• Your insurance copay is under $100 per month
• You qualify for the manufacturer savings card (commercial insurance, diabetes indication)
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen

The decision is patient-specific. A licensed provider should review your insurance status, out-of-pocket cost, and clinical needs before recommending either option.

How to verify your specific coverage in 10 minutes

Step 1: Log into your insurance member portal. Most plans publish their formulary (list of covered medications) online. Search for "semaglutide," "tirzepatide," "Ozempic," "Wegovy," "Mounjaro," or "Zepbound."

Step 2: Check the formulary tier and coverage notes. If the medication is listed, note:

• Which tier (Tier 1, 2, 3, specialty)
• Whether prior authorization is required
• Any coverage restrictions (diabetes only, step therapy required, quantity limits)

Step 3: Call the member services number on your insurance card. Ask: "Does my plan cover [medication name] for weight loss, or only for diabetes?" The representative can tell you on the phone.

Step 4: Ask your provider's office to run a test claim. Many provider offices can submit a test claim to your insurance without filling the prescription. This returns your exact copay and whether PA is required.

Step 5: If PA is required, ask what documentation is needed. The insurance company or your provider's office can tell you what labs, BMI records, and prior treatment history the PA requires.

This 10-minute verification prevents the most common surprise: a $400 copay you weren't expecting, or a denial after you assumed coverage.

FAQ

Does insurance cover Ozempic for weight loss? Most commercial insurance plans do not cover Ozempic for weight loss because it's FDA-approved only for type 2 diabetes. Some plans cover it off-label for weight loss with prior authorization, but denial rates exceed 60%. Medicare and most state Medicaid programs exclude weight loss coverage.

Does Medicare cover weight loss medication? No. Medicare Part D is prohibited by federal law from covering medications prescribed for weight loss. Some Medicare Advantage plans offer limited supplemental coverage for weight loss drugs, but fewer than 15% of plans include this benefit, and copays are typically $200 to $600 per month.

Does Medicaid cover Wegovy or Zepbound? Coverage varies by state. As of 2026, 19 states cover at least one GLP-1 medication for weight loss under Medicaid, usually with prior authorization. Most states cover GLP-1s only for diabetes. Check your state Medicaid formulary or call member services.

What is prior authorization and how long does it take? Prior authorization is a review process where your insurance company evaluates whether a medication is medically necessary before agreeing to cover it. Your provider submits documentation (labs, BMI, diagnosis, prior treatments). Approval or denial typically takes 3 to 14 business days. If denied, you can appeal, which takes another 30 to 60 days.

Why does insurance cover diabetes medication but not weight loss medication? Many insurance plans classify weight loss medications as "lifestyle drugs" or "cosmetic," similar to how they exclude coverage for gym memberships or nutritional supplements. The clinical evidence shows GLP-1s reduce cardiovascular events and prevent diabetes progression, but formulary rules often lag behind the evidence. Federal Medicare law explicitly excludes weight loss drugs.

Can I appeal if my insurance denies coverage? Yes. If your prior authorization is denied, you have the right to appeal. Appeal success rates are 45% to 55% for weight loss indications when the denial was due to insufficient documentation. If the denial was due to a formulary exclusion (the plan doesn't cover weight loss drugs at all), appeal success rates drop to 10% to 15%.

Does Blue Cross Blue Shield cover weight loss medication? Blue Cross Blue Shield is a network of independent insurers, so coverage varies by state and plan. Some BCBS plans cover GLP-1s for weight loss with prior authorization. Most cover them only for diabetes. Check your specific plan's formulary or call the member services number on your card.

Does UnitedHealthcare cover Wegovy or Mounjaro for weight loss? UnitedHealthcare's coverage depends on whether you have a fully insured plan (UHC sets the rules) or a self-funded employer plan (your employer sets the rules). As of 2026, UnitedHealthcare's standard commercial formulary covers Wegovy and Zepbound for weight loss with prior authorization, but many employer plans exclude them. Check your plan documents.

What if my employer plan excludes weight loss drugs? If your employer plan has a formulary exclusion, appeals rarely succeed because the plan doesn't cover the category. Your options are to pay cash ($1,000+ per month for brand-name), use a manufacturer savings card if eligible (commercial insurance only, diabetes indication only), or switch to compounded semaglutide or tirzepatide ($179 to $399 per month).

Does insurance cover compounded semaglutide? No. Compounded medications are not covered by insurance because they're not FDA-approved drugs with NDC codes. Compounded semaglutide and tirzepatide are cash-pay only. Some patients use HSA or FSA funds to pay for compounded medications.

How much does weight loss medication cost without insurance? Brand-name Wegovy costs $1,300 to $1,500 per month without insurance. Zepbound costs $1,050 to $1,200 per month. Ozempic (off-label for weight loss) costs $900 to $1,000 per month. Compounded semaglutide costs $179 to $279 per month. Compounded tirzepatide costs $279 to $399 per month.

Can I use a GoodRx coupon for Wegovy or Ozempic? Yes, but the discount is minimal. GoodRx coupons typically reduce Wegovy from $1,400 to $1,200, and Ozempic from $950 to $850. GoodRx doesn't work with insurance (you use one or the other, not both). For most patients, compounded alternatives are cheaper than GoodRx cash prices for brand-name GLP-1s.

Sources

1. Cubanski J et al. Medicare Coverage of Weight Loss Drugs. Health Affairs. 2025.
2. National Alliance of Healthcare Purchaser Coalitions. Employer Coverage of GLP-1 Medications Survey. 2025.
3. Kaiser Family Foundation. Medicare Advantage Supplemental Benefits Analysis. 2024.
4. Neuman T et al. Out-of-Pocket Costs for Weight Loss Medications in Medicare Advantage. KFF Report. 2024.
5. National Association of Medicaid Directors. State Medicaid Coverage of Anti-Obesity Medications. Policy Brief. 2025.
6. Milliman Research Report. Long-Term Cost Impact of GLP-1 Coverage in Employer Plans. 2024.
7. American Medical Association. Prior Authorization Physician Survey: GLP-1 Medications. 2024.
8. CVS Caremark. Formulary Denial and Appeal Rates Report. 2024-2025.
9. Express Scripts. Drug Trend Report: Specialty Medications. 2025.
10. OptumRx. Prior Authorization Outcomes for Diabetes and Obesity Medications. 2024.
11. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2023.
12. Social Security Act, Section 1860D-2(e)(2)(A). Medicare Part D Exclusions.
13. Peterson-KFF Health System Tracker. Insurance Coverage of Anti-Obesity Medications. 2025.
14. Kaiser Family Foundation. Employer Health Benefits Survey. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Blue Cross Blue Shield, UnitedHealthcare, CVS Caremark, Express Scripts, and OptumRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.